WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006088447) AN ANTI-CD137 ANTIBODY AS AN AGENT IN THE TREATEMENT OF CANCER AND GLYCOSYLATION VARIANTS THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/088447    International Application No.:    PCT/US2005/004739
Publication Date: 24.08.2006 International Filing Date: 15.02.2005
IPC:
C07K 16/00 (2006.01), A61K 39/395 (2006.01), C12P 21/00 (2006.01)
Applicants: GTC BIOTHERAPEUTICS, INC. [US/US]; 175 Crossing Boulevard, Suite 410, Framingham, MA 01702 (US) (For All Designated States Except US).
STROME, Scott, E. [US/US]; (US) (For US Only).
SCHINDLER, Daniel [US/US]; (US) (For US Only).
CHEN, Lieping [US/US]; (US) (For US Only).
MEADE, Harry [US/US]; (US) (For US Only)
Inventors: STROME, Scott, E.; (US).
SCHINDLER, Daniel; (US).
CHEN, Lieping; (US).
MEADE, Harry; (US)
Agent: SIEKMAN, Michael, T.; Wolf, Greenfield & Sacks, P.C., 600 atlantic Avenue, Boston, MA 02139 (US)
Priority Data:
Title (EN) AN ANTI-CD137 ANTIBODY AS AN AGENT IN THE TREATEMENT OF CANCER AND GLYCOSYLATION VARIANTS THEREOF
(FR) ANTICORPS ANTI-CD137 EN TANT QU'AGENT DANS LE TRAITEMENT DE CANCERS ET VARIANTE DE GLYCOSYLATION DUDIT ANTICORPS
Abstract: front page image
(EN)The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as an anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred imbodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals.
(FR)La présente invention concerne le développement et les méthodes d'application d'un anticorps agoniste recombinant anti-CD137 humaine, ainsi que des variantes de glycosylation dudit anticorps. Ces anticorps agissent en tant qu'agents anticancéreux et/ou immunorégulateurs et peuvent être employés pour réduire les tumeurs solides ou d'autres états cancéreux, et empêcher leur réapparition. Les types de cancers contre lesquels l'anticorps selon l'invention est efficace incluent également la leucémie et le lymphome. Dans un mode d'application préféré de l'invention, les anticorps recombinants selon l'invention sont produits dans le lait d'animaux transgéniques, et purifiés à partir de ce même lait.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)